Resources from the same session
LBA60 - Phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)
Presenter: Zhi Peng
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
Slides
Webcast
1402MO - An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophageal cancer
Presenter: Margaret Lee
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
Slides
Webcast
LBA63 - A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy
Presenter: Hanneke Wilmink
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
Slides
Webcast
1504MO - Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
Presenter: Wungki Park
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA63 and 1504MO
Presenter: Arndt Vogel
Session: Mini oral session: GI tumours, upper
Resources:
Slides
Webcast
965MO - Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW
Presenter: Thomas Decaens
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
Slides
Webcast
947MO - Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Lorenza Rimassa
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
Slides
Webcast
Invited Discussant 965MO and 947MO
Presenter: James Harding
Session: Mini oral session: GI tumours, upper
Resources:
Slides
Webcast